Cargando…

Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy

Seasonal influenza is caused by two subtypes of influenza A and two lineages of influenza B. Although trivalent influenza vaccines (TIVs) contain both circulating A strains, they contain only a single B-lineage strain. This can lead to mismatches between the vaccine and predominant circulating B lin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mennini, Francesco Saverio, Bini, Chiara, Marcellusi, Andrea, Rinaldi, Alessandro, Franco, Elisabetta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149987/ https://www.ncbi.nlm.nih.gov/pubmed/29708843 http://dx.doi.org/10.1080/21645515.2018.1469368

Ejemplares similares

Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis
por: Bianculli, Pablo Manuel, et al.
Publicado: (2022)

Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population
por: Tavares, Diana, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina
por: Urueña, Analia, et al.
Publicado: (2021)

Public health and economic impact of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Mexico
por: Ruiz-Palacios, Guillermo M., et al.
Publicado: (2019)

Public health and budget impacts of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Paraguay
por: Arbo, Antonio, et al.
Publicado: (2022)

The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland
por: Nagy, Lisa, et al.
Publicado: (2016)

Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: an overview of systematic reviews
por: Carregaro, Rodrigo Luiz, et al.
Publicado: (2023)

The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia
por: de Boer, Pieter T., et al.
Publicado: (2018)

Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong
por: You, Joyce HS, et al.
Publicado: (2014)

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults
por: Beran, Jiří, et al.
Publicado: (2013)

Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea
por: Kim, Yun-Kyung, et al.
Publicado: (2018)

Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines Against Influenza B in the United States, 2011–2012 to 2016–2017
por: Gaglani, Manjusha, et al.
Publicado: (2020)

HPV Vaccination during the COVID-19 Pandemic in Italy: Opportunity Loss or Incremental Cost
por: Mennini, Francesco Saverio, et al.
Publicado: (2022)

A Randomized Trial of Candidate Inactivated Quadrivalent Influenza Vaccine versus Trivalent Influenza Vaccines in Children Aged 3–17 Years
por: Domachowske, Joseph B., et al.
Publicado: (2013)

Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies
por: Liu, Xiaoqiang, et al.
Publicado: (2022)

Cost of illness del carcinoma cutaneo a cellule squamose (CSCC)
por: Marcellusi, Andrea, et al.
Publicado: (2020)

Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model
por: Dolk, Christiaan, et al.
Publicado: (2016)

Economic Burden of Human Papillomavirus-Related Diseases in Italy
por: Baio, Gianluca, et al.
Publicado: (2012)

Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years
por: Kieninger, Dorothee, et al.
Publicado: (2013)

Correction: Economic Burden of Human Papillomavirus-Related Diseases in Italy
por: Baio, Gianluca, et al.
Publicado: (2013)

Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe
por: Uhart, Mathieu, et al.
Publicado: (2016)

Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach
por: Brogan, Anita J., et al.
Publicado: (2016)

Cost-utility of quadrivalent versus trivalent influenza vaccine in Brazil – comparison of outcomes from different static model types
por: Van Bellinghen, Laure-Anne, et al.
Publicado: (2018)

Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017–2018 and 2018–2019 Influenza Seasons
por: Boikos, Constantina, et al.
Publicado: (2021)

Immunogenicity and safety of Quadrivalent Influenza HA vaccine compared with Trivalent Influenza HA vaccine and evaluation of Quadrivalent Influenza HA vaccine batch-to-batch consistency in Indonesian children and adults
por: Fadlyana, Eddy, et al.
Publicado: (2023)

Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy
por: Mennini, Francesco Saverio, et al.
Publicado: (2017)

Economic burden of schizophrenia in Italy: a probabilistic cost of illness analysis
por: Marcellusi, Andrea, et al.
Publicado: (2018)

Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines
por: Thommes, Edward W., et al.
Publicado: (2016)

Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model
por: Rudenko, Larisa, et al.
Publicado: (2018)

Estimation of the number of HCV-positive patients in Italy
por: Gardini, Ivan, et al.
Publicado: (2019)

Modelling the Economic Impact of lnfluenza Vaccine Programs with the Cell-Based Quadrivalent Influenza Vaccine and Adjuvanted Trivalent Influenza Vaccine in Canada
por: Nguyen, Van Hung, et al.
Publicado: (2022)

Trivalent and quadrivalent influenza vaccination effectiveness in Australia and South Africa: results from a modelling study
por: Milne, George J., et al.
Publicado: (2016)

From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain
por: Crépey, Pascal, et al.
Publicado: (2020)

Valutazione delle conseguenze epidemiologiche ed economiche generate dal ritardo di trattamento dei pazienti HIV-positivi causato dalla pandemia COVID-19
por: Marcellusi, Andrea, et al.
Publicado: (2021)

Analisi di impatto di budget di un nuovo sistema di cura in pazienti affetti da malattia di Parkinson
por: Bini, Chiara, et al.
Publicado: (2022)

Valutazione economica di treosulfan in pazienti sottoposti a trapianto allogenico di cellule staminali ematopoietiche
por: Bini, Chiara, et al.
Publicado: (2022)

Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax(®) Tetra/Flucelvax Quadrivalent(®)): A Review in the Prevention of Influenza
por: Lamb, Yvette N.
Publicado: (2019)

An Analysis of the Social and Economic Costs of Breast Cancer in Italy
por: Mennini, Francesco Saverio, et al.
Publicado: (2021)

Impact of adjuvant: Trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus
por: Myers, Mallory L., et al.
Publicado: (2022)

Correction to: Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax(®) Tetra/Flucelvax Quadrivalent(®)): A Review in the Prevention of Influenza
por: Lamb, Yvette N.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_350safkb4hpqmkjknhre6nlatd